Curated News
By: NewsRamp Editorial Staff
March 20, 2026
Co-Diagnostics Expands South Asian Reach, Targets $13B Market
TLDR
- Co-Diagnostics gains a strategic advantage by expanding its Indian joint venture's market reach to four South Asian countries, potentially accessing a $13 billion market.
- Co-Diagnostics' joint venture CoSara Diagnostics will expand distribution across Bangladesh, Pakistan, Nepal and Sri Lanka, pending regulatory approvals for its PCR Pro platform and SARAGENE products.
- This expansion could improve healthcare access in South Asia by deploying molecular diagnostics solutions to detect infectious diseases more effectively at point-of-care locations.
- Co-Diagnostics' joint venture is targeting a massive $13 billion market across four countries with its PCR technology for molecular diagnostics.
Impact - Why it Matters
This expansion matters because it represents a strategic move to bring advanced, rapid molecular diagnostics to populous regions in South Asia with significant unmet healthcare needs. By targeting a combined market worth an estimated $13 billion, Co-Diagnostics is not just pursuing growth but potentially improving public health outcomes. The planned deployment of point-of-care platforms like CoSara PCR Pro could enable faster, more accessible testing for infectious diseases in areas where lab infrastructure may be limited. For the global diagnostics market, this signals increasing competition and innovation in emerging economies, which could drive down costs and improve technology adoption worldwide. For investors, it highlights a company executing an aggressive international growth strategy in a high-demand sector.
Summary
Co-Diagnostics (NASDAQ: CODX), a molecular diagnostics company, has announced a significant expansion for its Indian joint venture, CoSara Diagnostics Pvt. Ltd. The venture has signed an agreement to extend its commercial and distribution territory across South Asia, now including Bangladesh, Pakistan, Nepal, and Sri Lanka. This strategic move dramatically increases the company's addressable market to an estimated $13.0 billion. The expansion is designed to support the planned commercialization of the CoSara PCR Pro(R) point-of-care platform and the SARAGENE(R) product line, pending necessary regulatory approvals. This effort is part of a broader strategy to build robust regional distribution channels and position the company for the wider deployment of its advanced molecular diagnostics solutions.
The company, which develops state-of-the-art diagnostics technologies for detecting nucleic acid molecules like DNA or RNA, is also leveraging its proprietary technology for its Co-Dx PCR at-home and point-of-care platform. It's important to note that this platform is subject to regulatory review and is not currently for sale. The press release was distributed via MissionIR, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. MissionIR assists IR firms by syndicating content to enhance company visibility, utilizing solutions like InvestorWire for press distribution and offering services such as article syndication to over 5,000 outlets, enhanced press release features, and social media distribution via IBN to millions of followers.
For investors and stakeholders seeking more detailed information, the full press release is available for viewing. MissionIR operates as a key node where breaking news, insightful content, and actionable information converge, helping companies cut through market noise to achieve unparalleled recognition and brand awareness. This announcement underscores Co-Diagnostics' aggressive growth strategy in emerging markets and its commitment to expanding access to critical diagnostic technologies in regions with substantial healthcare needs.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Co-Diagnostics Expands South Asian Reach, Targets $13B Market
